APAC Antibiotics Market

APAC Antibiotics Market Size (2023 to 2028)

The size of the Antibiotics market in the Asia-Pacific is projected to be growing at a CAGR of 6.1% between 2023 to 2028.

Antibiotics can kill or slow down bacterial growth and are widely used to cure and prevent diseases caused by bacteria. The major growth factors for the APAC antibiotics market are the increasing prevalence of animal diseases, fluctuations in demographics, and growing consumption of meat. Also, the number of patients suffering from infectious diseases and diagnostic devices' developments is expected to accelerate the Asia Pacific antibiotics market.

In addition, the increase in the prevalence of cardiovascular illness and the increased demand for antibodies for research reproductivity are expected to act favorably to the market's growth rate. Also, the government expenditures in reducing healthcare costs and enhanced development efforts to provide better diagnostic treatment, the market in this sector are developing. Further, investing in medications and enhancing the healthcare system aid in the growth of the antibiotic market.

Furthermore, the antibiotics market growth in this region is driven by the rising antibiotic consumption in developing countries such as India and China. Government incentives for better market expansion of antibiotics in Asian countries, pharmaceutical companies R&D activities on antibiotics are more likely to expand market growth. Advanced prospect molecules and the evolution of novel combination therapies to cure antibiotic-resistant microbial infections propel market growth. 

However, the development of antibiotic resistance and the rise in drug approval costs are expected to restrain the market growth. In addition, the variations in the antibodies affect the results of research and clinical screening tests. Moreover, technologies require large bioreactors and filtration systems for antibody production, another significant burden on the market players. Also, poor standards for the validation reproducibility across every antibody offering impede the market growth. 

Impact of COVID-19 on APAC Antibiotics market:

The outbreak of covid-19 has shown a mixed impact on the pharmaceutical and life sciences industries. The explosion of COVID-19 has positively impacted the antibody market growth in the Asia Pacific. The research activities on antibiotics are boosting because of the efforts to understand the dynamics of infection. The scientific community works tirelessly to find out a suitable treatment for COVID-19. The latest technologies of genetic and molecular testing are being used to test the COVID-19. Research and reagent manufacturing with personalized medicine will further have growth. The antibiotics market has witnessed the largest market share during the covid-19 period. However, the market is expected to increase its growth in the coming years. 

This research report on the Asia-Pacific antibiotics market has been segmented and sub-segmented into the following categories.

By Action Mechanism:

• Cell Wall Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Rna Synthesis Inhibitors
• Mycolic Acid Synthesis Inhibitors
• Folic Acid Synthesis Inhibitors

By Drug Class:

• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Aminoglycosides
• Sulfonamides
• Others

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the Asia Pacific antibiotics market is predicted to achieve a substantial share during the forecast period. In addition, the growing adoption of strategies such as mergers and acquisitions by the key market players and rising investments by the organizations is to help the market.

The Chinese antibiotics market is expected to account for the majority of the share in the APAC witnessed the largest market share of the antibiotics market during the forecast period due to the increase in the prevalence of chronic diseases, the rapid rise in the consumption of antibiotics.  China is expected to have an increase in the growth of the market as it is at the top in terms of the population rate, therefore as per the 2020 census, China's population of individuals aged 60 and above was estimated to be 264 million, that is the 18.70 percent of the total population, which has increased from 13.3 percent in the 2010 census, which is leading to the rise in the growth of geriatric population in these regions as well as with the increase in the disease prevalence.

The Indian antibiotics market is another lucrative regional market in APAC and is estimated to hike at a healthy rate during the forecast period. In the recent period, the COVID-19 Pandemic has increased the usage of antibiotics in India. In addition, the Indian government initiatives and policies are further helping the market to flourish during the forecast period, which can be done by investing in medications and upgrading healthcare infrastructure. Also, the growth in further technological advancements, which will give greater accessibility and rising disposable income, will all positively affect the industry's growth.

Countries such as Japan and Australia are expected to grow at a steady rate during the forecast period. Rising government incentives to develop novel therapies for treating drug-resistant infections and generic players' presence encourages market growth in this region. Moreover, a rise in the treatment spending capacities on contemporary medications will also benefit the market size. Companies are also adjusting to the rapid change in the market by refocusing their business plans and strategies to support the growth of the antibody industry.

KEY MARKET PLAYERS:

Companies playing a significant role in the Asia-Pacific antibiotics market covered in this report are Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG.